HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.

Abstract
In human ovarian carcinoma, the endothelin-1 (ET-1) / endothelin A receptor (ETAR) axis is overexpressed, correlating with tumor grade. Moreover, ETAR activation by ET-1 affects cell proliferation, survival, angiogenesis, and invasion. ETAR blockade with zibotentan (ZD4054), a specific ETAR antagonist, significantly inhibits ovarian cancer growth in vitro and in vivo, underscoring the relevance of this pathway as a target for cancer therapy. Since clinical trial results have defined the combination of platinum and taxane as the standard of care in the management of ovarian cancer, here we explored the therapeutic efficacy of the integration of zibotentan with cytotoxic drugs having different modes of action. We found that the combination of zibotentan with cisplatinum as well as zibotentan with paclitaxel was more effective at inhibiting ovarian cancer HEY cell proliferation induced by endogenous ET-1 than were the single agents alone. However, a significantly enhanced efficacy was observed when we combined zibotentan, cisplatinum, and paclitaxel. Accordingly, in HEY xenografts the coadministration of zibotentan with cisplatinum enhanced the efficacy of the cytotoxic drug alone in controlling tumor growth, associated with reduction in proliferation index and microvessel density. Remarkably, the combination of zibotentan with both cisplatinum and paclitaxel was very effective in inhibiting tumor growth, neovascularization, and cell proliferation, representing a preclinical endpoint to guide combination therapy in clinical trials.
AuthorsLaura Rosanò, Roberta Cianfrocca, Francesca Spinella, Valeriana Di Castro, Pier Giorgio Natali, Anna Bagnato
JournalCanadian journal of physiology and pharmacology (Can J Physiol Pharmacol) Vol. 88 Issue 6 Pg. 676-81 (Jun 2010) ISSN: 1205-7541 [Electronic] Canada
PMID20628434 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Endothelin A Receptor Antagonists
  • Ki-67 Antigen
  • Pyrrolidines
  • ZD4054
  • Paclitaxel
  • Cisplatin
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cisplatin (administration & dosage, pharmacology, therapeutic use)
  • Drug Therapy, Combination (methods)
  • Endothelin A Receptor Antagonists
  • Female
  • Humans
  • Ki-67 Antigen (metabolism)
  • Mice
  • Mice, Nude
  • Neoplasms, Glandular and Epithelial (drug therapy, metabolism, pathology)
  • Neovascularization, Pathologic (drug therapy, pathology)
  • Ovarian Neoplasms (drug therapy, metabolism, pathology)
  • Paclitaxel (administration & dosage, pharmacology, therapeutic use)
  • Pyrrolidines (administration & dosage, pharmacology, therapeutic use)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: